医薬品有効成分（API）の世界市場予測（～2024年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.3 MARKET SCOPE 27
1.3.1 MARKETS COVERED 27
1.3.2 YEARS CONSIDERED FOR THE STUDY 28
1.4 CURRENCY 29
1.5 LIMITATIONS 29
1.6 STAKEHOLDERS 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
2.1.1 SECONDARY SOURCES 31
2.1.1.1 Key Data from Secondary Sources 31
2.1.2 PRIMARY SOURCES 32
2.1.2.1 Key Data from Primary Sources 33
2.1.2.2 Key Industry Insights 34
2.2 MARKET SIZE ESTIMATION 35
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 37
2.4 MARKET SHARE ESTIMATION 38
2.5 ASSUMPTIONS FOR THE STUDY 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 44
4.1 ACTIVE PHARMACEUTICAL INGREDIENTS: MARKET OVERVIEW 44
4.2 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 45
4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER 45
4.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 46
4.5 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 47
4.6 GEOGRAPHIC SNAPSHOT: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
5.2.1 DRIVERS 49
5.2.1.1 Increasing incidence of chronic diseases 49
5.2.1.2 Technological advancements in API manufacturing 50
5.2.1.3 Growing importance of generics 50
5.2.1.4 Increasing uptake of biopharmaceuticals 51
5.2.1.5 Growing adoption of artificial intelligence-based tools for drug discovery 52
5.2.1.6 Adoption of organ-on-chip models in drug development 53
5.2.1.7 Growing focus on precision medicine 53
5.2.1.8 Growing investments in real-world evidence by pharmaceutical companies 54
5.2.2 RESTRAINTS 55
5.2.2.1 Unfavorable drug price control policies across various countries 55
5.2.2.2 Increasing penetration of counterfeit drugs 55
5.2.3 OPPORTUNITIES 56
5.2.3.1 Emerging biosimilars market 56
5.2.3.2 Highly potent active pharmaceutical ingredients 56
5.2.3.3 Emerging markets 57
5.2.3.4 Emerging technologies 57
5.2.4 CHALLENGES 57
5.2.4.1 Product differentiation – A major concern for API manufacturers 57
5.2.4.2 High manufacturing costs 58
6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 59
6.1 INTRODUCTION 60
6.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS 61
6.2.1 GROWING NUMBER OF NEW MOLECULAR ENTITIES GAINING REGULATORY APPROVAL TO DRIVE MARKET GROWTH 61
6.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS 63
6.3.1 GOVERNMENT INITIATIVES SUPPORTING THE ADOPTION OF GENERIC DRUGS TO BOOST MARKET GROWTH 63
7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF MANUFACTURER 64
7.1 INTRODUCTION 65
7.2 CAPTIVE API MANUFACTURERS 66
7.2.1 HIGH MANUFACTURING FLEXIBILITY AND ASSURANCE OF PRODUCT QUALITY HAVE DRIVEN FOCUS ON CAPTIVE MANUFACTURING 66
7.3 MERCHANT API MANUFACTURERS 67
7.3.1 MERCHANT API MANUFACTURERS MARKET, BY TYPE 68
7.3.1.1 Merchant Innovative API Manufacturers 69
7.3.1.1.1 Impending patent expiries and increasing costs of innovative drugs may restrain market growth 69
7.3.1.2 Merchant Generic API Manufacturers 70
7.3.1.2.1 Low manufacturing cost of generics likely to drive the growth of this segment 70
 
7.3.2 MERCHANT API MANUFACTURERS MARKET, BY TYPE OF SYNTHESIS 70
7.3.2.1 Merchant Synthetic API Manufacturers 71
7.3.2.1.1 Need for specialized manufacturing capabilities has resulted in expansion among market players in this segment 71
7.3.2.2 Merchant Biotech API Manufacturers 72
7.3.2.2.1 Complexity of manufacturing biotech APIs has driven focus on partnerships between companies and CMOs 72
8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 74
8.1 INTRODUCTION 75
8.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS 76
8.2.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 77
8.2.1.1 Innovative synthetic APIs 77
8.2.1.1.1 The high value of innovative APIs to drive the growth of this segment 77
8.2.1.2 Generic synthetic APIs 78
8.2.1.2.1 Initiatives to promote the penetration of generics to bring down healthcare costs—a major growth driver 78
8.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS 79
8.3.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 81
8.3.1.1 Innovative biotech APIs 81
8.3.1.1.1 Growing demand for innovative biopharmaceuticals to drive the market for this segment 81
8.3.1.2 Generic biotech APIs 82
8.3.1.2.1 Increasing demand for biosimilar drugs due to their cost-effectiveness to drive the growth of this segment 82
8.3.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 84
8.3.2.1 Monoclonal antibodies 85
8.3.2.1.1 Growing applications of antibody-drug conjugates in the treatment of cancer to drive the growth of this segment 85
8.3.2.2 Hormones & growth factors 86
8.3.2.2.1 The growing incidence of hormonal disorders to drive the market for this segment 86
8.3.2.3 Cytokines 87
8.3.2.3.1 Interferons and interleukins boost the immune system and have important applications in cancer treatment 87
8.3.2.4 Fusion proteins 88
8.3.2.4.1 Growing applications of Fc fusion proteins in biopharmaceuticals to drive the growth of this segment 88
8.3.2.5 Recombinant vaccines 89
8.3.2.5.1 Growing prevalence of infectious diseases has boosted vaccine development—a positive indicator of growth 89
8.3.2.6 Therapeutic enzymes 90
8.3.2.6.1 Growing significance of enzymes in therapies for cancer and pain management to drive the growth of this segment 90
8.3.2.7 Blood factors 90
8.3.2.7.1 Growing incidence of hemophilia to drive the growth of this segment 90
8.3.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM 91
8.3.3.1 Mammalian expression systems 92
8.3.3.1.1 Ability of these systems to carry post-translational modification to drive the market for this segment 92
8.3.3.2 Microbial expression systems 93
8.3.3.2.1 Ability of these expression systems to provide high expression levels of proteins to drive the market for this segment 93
8.3.3.3 Yeast expression systems 93
8.3.3.3.1 Advantages such as efficient protein secretion, simple purification, and endotoxin-free products to boost demand 93
8.3.3.4 Insect expression systems 94
8.3.3.4.1 Efficient post-translational modifications provided by these systems to boost their demand 94
8.3.3.5 Other expression systems 95
9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 96
9.1 INTRODUCTION 97
9.2 PRESCRIPTION DRUGS 98
9.2.1 GROWING DISEASE PREVALENCE IS EXPECTED TO DRIVE THE PRESCRIPTION DRUGS MARKET 98
9.3 OVER-THE-COUNTER DRUGS 99
9.3.1 SALES OF OTC DRUGS HAVE RISEN DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS 99
9.4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY 100
9.4.1 LOW-TO-MODERATE POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS 100
9.4.2 POTENT-TO-HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS 101
10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION 103
10.1 INTRODUCTION 104
10.2 COMMUNICABLE DISEASES 105
10.2.1 GLOBAL HEALTH IMPACT OF COMMUNICABLE DISEASES AND INCREASING ANTIMICROBIAL RESISTANCE—KEY MARKET DRIVERS 105
10.3 ONCOLOGY 106
10.3.1 INCREASE IN GLOBAL SPENDING ON CANCER MEDICATION TO BOOST THE MARKET FOR THIS SEGMENT 106
10.4 PAIN MANAGEMENT 108
10.4.1 INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS IS A MAJOR GROWTH DRIVER FOR THIS MARKET 108
 
10.5 CARDIOVASCULAR DISEASES 109
10.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES IS A MAJOR GROWTH DRIVER 109
10.6 DIABETES 110
10.6.1 HIGH GLOBAL PREVALENCE OF DIABETES TO DRIVE THE GROWTH OF THIS SEGMENT 110
10.7 RESPIRATORY DISEASES 111
10.7.1 HIGH GLOBAL PREVALENCE OF RESPIRATORY DISEASES TO DRIVE THE GROWTH OF THIS SEGMENT 111
10.8 OTHER THERAPEUTIC APPLICATIONS 111
11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION 113
11.1 INTRODUCTION 114
11.2 NORTH AMERICA 114
11.2.1 US 121
11.2.1.1 Increasing expenditure on medicine is expected to drive the APIs market in the US 121
11.2.2 CANADA 126
11.2.2.1 Support from government organizations is driving the growth of the APIs market in Canada 126
11.3 EUROPE 130
11.3.1 GERMANY 137
11.3.1.1 Germany to dominate the market in Europe 137
11.3.2 FRANCE 142
11.3.2.1 Emergence of pharmerging markets in Asia may hinder market growth in France 142
11.3.3 UK 147
11.3.3.1 Growing adoption of generics will drive the growth of the UK market 147
11.3.4 ITALY 152
11.3.4.1 Italy’s share in the global merchant APIs market is expected to remain stable over the forecast period 152
11.3.5 SPAIN 157
11.3.5.1 Spanish market has been typically dominated by branded drugs 157
11.3.6 REST OF EUROPE 162
11.4 ASIA 166
11.4.1 JAPAN 172
11.4.1.1 Japanese government aims to boost the use of generics by 2020 172
11.4.2 CHINA 177
11.4.2.1 Government policies to increase medicine access and affordability will support market growth 177
11.4.3 INDIA 181
11.4.3.1 India is a leading producer of generics 181
 
11.4.4 SOUTH KOREA 186
11.4.4.1 Government initiatives to introduce full medical coverage for major chronic diseases likely to drive this market 186
11.4.5 REST OF ASIA 190
11.5 REST OF THE WORLD 195
12 COMPETITIVE LANDSCAPE 200
12.1 OVERVIEW 200
12.2 MARKET PLAYER RANKING 202
12.3 COMPETITIVE LEADERSHIP MAPPING 204
12.3.1 VANGUARDS 204
12.3.2 DYNAMIC DIFFERENTIATORS 204
12.3.3 INNOVATORS 204
12.3.4 EMERGING PLAYERS 204
12.4 COMPETITIVE SITUATION AND TRENDS 206
12.4.1 PRODUCT LAUNCHES 206
12.4.2 EXPANSIONS 206
12.4.3 ACQUISITIONS 207
12.4.4 OTHER STRATEGIES 207
13 COMPANY PROFILES 209
(Business overview, Products offered, Recent Developments, MNM view)*
13.1 PFIZER, INC. 209
13.2 NOVARTIS AG 212
13.3 SANOFI 215
13.4 BOEHRINGER INGELHEIM 219
13.5 BRISTOL-MYERS SQUIBB 222
13.6 TEVA PHARMACEUTICAL INDUSTRIES LTD. 226
13.7 ELI LILLY AND COMPANY 229
13.8 GLAXOSMITHKLINE PLC 232
13.9 MERCK & CO., INC. 235
13.10 ABBVIE INC. 238
13.11 F. HOFFMANN-LA ROCHE 242
13.12 ASTRAZENECA 244
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
 
14 APPENDIX 246
14.1 DISCUSSION GUIDE 246
14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 250
14.3 AVAILABLE CUSTOMIZATIONS 252
14.4 RELATED REPORTS 252
14.5 AUTHOR DETAILS 253